Table 2.
Potential metabolites involved in sarcopenia
| Method | Features | HMDB ID | FC (patient/control) | P value (patient vs. control) | FDR value (patient vs. control) | VIP score (patient vs. control) | AUC (patient vs. control) | FC (post‐intervention/pre‐intervention) | P value (pre‐intervention vs. post‐intervention) |
|---|---|---|---|---|---|---|---|---|---|
| NMR | Isoleucine | HMDB0000172 | 0.86 ± 0.04 | 0.0005 | 0.011 | 1.063 | 0.7606 | 1.01 ± 0.70 | 0.9177 |
| Carnitine | HMDB0000062 | 1.05 ± 0.01 | 0.0110 | 0.060 | 1.070 | 0.7167 | 0.97 ± 0.05 | 0.0963 | |
| LC–MS | 1‐Methylhistamine/3‐methylhistamine | HMDB0000898/HMDB0001861 | 1.24 ± 0.14 | 0.0039 | 0.004 | 1.054 | 0.7074 | 0.77 ± 0.03 | 0.0004 |
| Creatinine | HMDB0000562 | 0.71 ± 0.04 | 1.93E‐05 | 0.001 | 1.355 | 0.8127 | 1.089 ± 0.19 | 0.1092 | |
| Carnosine | HMDB0000033 | 0.71 ± 0.04 | 0.0007 | 0.011 | 2.567 | 0.7867 | 1.32 ± 0.15 | 0.0423 | |
| Ureidopropionic acid | HMDB0000026 | 0.61 ± 0.10 | 0.0107 | 0.034 | 3.309 | 0.7012 | 1.01 ± 0.67 | 0.9236 | |
| Uric acid | HMDB0000289 | 0.88 ± 0.03 | 0.0083 | 0.037 | 1.512 | 0.7034 | 1.02 ± 0.24 | 0.6152 | |
| PC (18:2/20:0) | HMDB0013436 | 0.69 ± 0.03 | 0.0010 | 0.046 | 2.369 | 0.7347 | 1.25 ± 0.07 | 0.0372 | |
| PC (20:2/18:0) | HMDB0008333 | 0.70 ± 0.06 | 0.0014 | 0.047 | 2.333 | 0.7357 | 1.24 ± 0.32 | 0.0557 | |
| PC (18:1/20:1) | HMDB0008077 | 0.74 ± 0.05 | 0.0015 | 0.042 | 2.065 | 0.7130 | 1.18 ± 0.13 | 0.1073 | |
| PI 32:1 | HMDB0009779 | 4.72 ± 0.17 | 0.0006 | 0.043 | 1.035 | 0.9272 | 0.28 ± 0.06 | 0.0020 | |
| PI 34:3 | HMDB0240614 | 1.88 ± 0.13 | 0.0003 | 0.039 | 1.006 | 0.7867 | 0.63 ± 0.11 | 0.0038 |
AUC, area under the receiver operating characteristic curve; FC, fold change; FDR, false discovery rate; PC, phosphatidylcholines; PI, phosphatidylinositol; VIP, variable importance in projection.